BioCentury | Sep 18, 2020
Emerging Company Profile

Synthekine launches with $82M to create new cytokine signals

...the IL-2 receptor’s β chain over  its α chain to boost anti-tumor immune responses was licensed by Medicenna Therapeutics...
BioCentury | Aug 29, 2020
Product Development

Next-wave Th1 cytokine cancer therapies aim for more precise targeting

...A/S (NASDAQ:ASND), Iovance Biotherapeutics Inc. (NASDAQ:IOVA) and Medicenna Therapeutics...
...Peak Therapeutics Neoleukin Therapeutics Inc. Ascendis Pharma A/S Iovance Biotherapeutics Inc. Medicenna Therapeutics...
BioCentury | Jun 25, 2020
Emerging Company Profile

Simcha launches with $25M WuXi-led series A, new take on IL-18 for cancer

...co-developed SIRPA variants that block wild-type SIRPA from binding CD47, a don’t-eat-me signal on tumors. Medicenna Therapeutics...
BioCentury | Jul 17, 2017
Company News

Management tracks

...named Gerrit Los CSO. He was VP of pharmacology at AnaptysBio Inc. (NASDAQ:ANAB). Oncology play Medicenna Therapeutics...
BioCentury | Apr 13, 2017
Clinical News

MDNA55: Ph IIb started

...using convection-enhanced delivery in about 43 patients who have progressed or recurred following previous therapy. Medicenna Therapeutics...
...Phase IIb started Milestone: Complete Phase IIb enrollment (year end 2017), Phase IIb data (1H18) Alicia Parker MDNA55 Medicenna Therapeutics...
BioCentury | Mar 17, 2017
Company News

Medicenna goes public

...Cancer company Medicenna Therapeutics Inc. went public via the acquisition of Canadian capital pool company A2 Acquisition Corp...
...to inquiries (see BioCentury, Dec. 15, 2016 ). Medicenna Therapeutics Corp. (TSX-V:MDNA), Toronto, Ontario Business: Cancer Alex Himes MDNA55 Medicenna Therapeutics...
BioCentury | Dec 15, 2016
Clinical News

MDNA55: Ph II started

...a single intratumoral infusion using convection-enhanced delivery of 1.5 µg/mL MDNA55 in about 43 patients. Medicenna Therapeutics Inc....
...Phase II started Milestone: Complete Phase II enrollment (year end 2017); Phase II data (1H18) Alicia Parker MDNA55 Medicenna Therapeutics Inc. Interleukin-4...
BioCentury | Apr 14, 2016
Strategy

Next stop: Houston

...Louis, Mo. 2008 Luciano Alleruzzo, Wei Chen, Tomas Hode, Robert Nordquist Cancer Autologous vaccine $8.6 Medicenna Therapeutics Inc....
BioCentury | Mar 14, 2016
Company News

J&J cancer news

...Several resident biotechs will focus on oncology and immuno-oncology, including Immunophotonics Inc. (Columbia, Mo.) and Medicenna Therapeutics Inc....
BioCentury | Mar 3, 2016
Company News

J&J launches JLABS incubator in Houston

...Several resident biotechs will focus on oncology and immuno-oncology, including Immunophotonics Inc. (Columbia, Mo.) and Medicenna Therapeutics Inc....
Items per page:
1 - 10 of 12
BioCentury | Sep 18, 2020
Emerging Company Profile

Synthekine launches with $82M to create new cytokine signals

...the IL-2 receptor’s β chain over  its α chain to boost anti-tumor immune responses was licensed by Medicenna Therapeutics...
BioCentury | Aug 29, 2020
Product Development

Next-wave Th1 cytokine cancer therapies aim for more precise targeting

...A/S (NASDAQ:ASND), Iovance Biotherapeutics Inc. (NASDAQ:IOVA) and Medicenna Therapeutics...
...Peak Therapeutics Neoleukin Therapeutics Inc. Ascendis Pharma A/S Iovance Biotherapeutics Inc. Medicenna Therapeutics...
BioCentury | Jun 25, 2020
Emerging Company Profile

Simcha launches with $25M WuXi-led series A, new take on IL-18 for cancer

...co-developed SIRPA variants that block wild-type SIRPA from binding CD47, a don’t-eat-me signal on tumors. Medicenna Therapeutics...
BioCentury | Jul 17, 2017
Company News

Management tracks

...named Gerrit Los CSO. He was VP of pharmacology at AnaptysBio Inc. (NASDAQ:ANAB). Oncology play Medicenna Therapeutics...
BioCentury | Apr 13, 2017
Clinical News

MDNA55: Ph IIb started

...using convection-enhanced delivery in about 43 patients who have progressed or recurred following previous therapy. Medicenna Therapeutics...
...Phase IIb started Milestone: Complete Phase IIb enrollment (year end 2017), Phase IIb data (1H18) Alicia Parker MDNA55 Medicenna Therapeutics...
BioCentury | Mar 17, 2017
Company News

Medicenna goes public

...Cancer company Medicenna Therapeutics Inc. went public via the acquisition of Canadian capital pool company A2 Acquisition Corp...
...to inquiries (see BioCentury, Dec. 15, 2016 ). Medicenna Therapeutics Corp. (TSX-V:MDNA), Toronto, Ontario Business: Cancer Alex Himes MDNA55 Medicenna Therapeutics...
BioCentury | Dec 15, 2016
Clinical News

MDNA55: Ph II started

...a single intratumoral infusion using convection-enhanced delivery of 1.5 µg/mL MDNA55 in about 43 patients. Medicenna Therapeutics Inc....
...Phase II started Milestone: Complete Phase II enrollment (year end 2017); Phase II data (1H18) Alicia Parker MDNA55 Medicenna Therapeutics Inc. Interleukin-4...
BioCentury | Apr 14, 2016
Strategy

Next stop: Houston

...Louis, Mo. 2008 Luciano Alleruzzo, Wei Chen, Tomas Hode, Robert Nordquist Cancer Autologous vaccine $8.6 Medicenna Therapeutics Inc....
BioCentury | Mar 14, 2016
Company News

J&J cancer news

...Several resident biotechs will focus on oncology and immuno-oncology, including Immunophotonics Inc. (Columbia, Mo.) and Medicenna Therapeutics Inc....
BioCentury | Mar 3, 2016
Company News

J&J launches JLABS incubator in Houston

...Several resident biotechs will focus on oncology and immuno-oncology, including Immunophotonics Inc. (Columbia, Mo.) and Medicenna Therapeutics Inc....
Items per page:
1 - 10 of 12